Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 1.62 million during the last session, with the company’s beta value hitting 1.12. At the close of trading, the stock’s price was $8.31, to imply an increase of 8.20% or $0.63 in intraday trading. The CRVS share’s 52-week high remains $8.33, putting it -0.24% down since that peak but still an impressive 87.36% since price per share fell to its 52-week low of $1.05. The company has a valuation of $519.79M, with an average of 0.97 million shares in intraday trading volume over the past 10 days and average of 532.67K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Corvus Pharmaceuticals Inc (CRVS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CRVS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
After registering a 8.20% upside in the last session, Corvus Pharmaceuticals Inc (CRVS) has traded red over the past five days. The 5-day price performance for the stock is 15.26%, and 63.26% over 30 days. With these gigs, the year-to-date price performance is 372.16%. Short interest in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw shorts transact 2.15 million shares and set a 4.15 days time to cover.
The extremes give us $7 and $12 for target low and target high price respectively. As such, CRVS has been trading -44.4% off suggested target high and 15.76% from its likely low.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
Looking at statistics comparing Corvus Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Corvus Pharmaceuticals Inc (CRVS) shares are 473.10% up over the last 6 months, with its year-to-date growth rate higher than industry average at 19.64% against 17.50%. Revenue is forecast to grow 8.30% this quarter before jumping 14.30% for the next one.
CRVS Dividends
Corvus Pharmaceuticals Inc has its next earnings report out on 2024-Nov-05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Corvus Pharmaceuticals Inc insiders hold 4.02% of total outstanding shares, with institutional holders owning 44.19% of the shares at 46.04% float percentage. In total, 44.19% institutions holds shares in the company, led by ORBIMED ADVISORS LLC. As of 2024-06-30, the company held over 6.94 million shares (or 14.1596% of shares), all amounting to roughly $12.64 million.
The next major institution holding the largest number of shares is SAMLYN CAPITAL, LLC with 6.12 million shares, or about 12.4861% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.14 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Corvus Pharmaceuticals Inc (CRVS) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.16 shares. This is just over 1.85% of the total shares, with a market valuation of $9.61 million. Data from the same date shows that the other fund manager holds a little less at 429.52, or 0.69% of the shares, all valued at about 3.57 million.
